Doctor Rafael Bravo-Marques

Back

Doctor Rafael Bravo-Marques

University Hospital Costa del Sol, Marbella (Spain)

Member of:

Presentations

Idiopathic pulmonary arterial hypertension, associated with connective tissue disease and comorbidities: prognostic differences? Results the Spanish Registry of pulmonary hypertension (REHAP Registry)

Event: ESC Congress 2024

Topic: Pulmonary Hypertension

Session: Pulmonary hypertension: insights from registries, retrospective data sets, and meta-analyses

Access

The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)

Event: ESC Congress 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Pulmonary hypertension: insights from registries, retrospective data sets, and meta-analyses

Access

Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study

Event: ESC Congress 2022

Topic: Pulmonary Hypertension

Session: Focus on the pulmonary vascular bed

Access

Efficacy and safety of selexipag in patients with pulmonary arterial hypertension in real-life: early results of RAMPHA study

Event: Heart Failure 2022

Topic: Pulmonary Hypertension

Session: Focus on the right side

Access

Security of neurohormonal blocking with sacubitril / valsartan, iSGLT2 and mineralocorticoid receptor antagonist in patients with heart failure with reduced eyection fraction and diabetes mellitus

Event: Heart Failure 2019

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy

Access

Sacubitril valsartan in real life: tolerance, clinical evolution and remodeled long term

Event: Heart Failure 2019

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy

Access

Experience using sacubitril/valsartan in real life: tolerability and clinical evolution in a long term

Event: Heart Failure 2018

Topic: Systolic Ventricular Dysfunction

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access

Initial experience using LCZ696 in real life: tolerability and clinical evolution in a short term.

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Hormones / neurohumoral regulation

Session: Hormones - Neurohumoral regulation

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Rafael Bravo-Marques Follow

Contributor content

Idiopathic pulmonary arterial hypertension, associated with connective tissue disease and comorbidities: prognostic differences? Results the Spanish Registry of pulmonary hypertension (REHAP Registry)

The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)

Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study

Efficacy and safety of selexipag in patients with pulmonary arterial hypertension in real-life: early results of RAMPHA study

Security of neurohormonal blocking with sacubitril / valsartan, iSGLT2 and mineralocorticoid receptor antagonist in patients with heart failure with reduced eyection fraction and diabetes mellitus

Sacubitril valsartan in real life: tolerance, clinical evolution and remodeled long term

Experience using sacubitril/valsartan in real life: tolerability and clinical evolution in a long term

Initial experience using LCZ696 in real life: tolerability and clinical evolution in a short term.

ESC 365 is supported by

Doctor Rafael Bravo-Marques